Cancer News: Colon

Bowel cancer patients need emotional and practical support

Bowel cancer patients with no psychological support after surgery, struggle with depression and poor well-being.

Nintedanib improves progression-free survival in metastatic colorectal cancer

Nintedanib (a multiple tyrosine kinase inhibitor) improves progression-free survival (PFS) in metastatic colorectal cancer.

The potential of adjuvant chemotherapy in early-stage colon cancer

Early-stage colon cancer patients who received adjuvant chemotherapy survived longer, a new retrospective study shows.

A diagnosis of high cholesterol led to increased cancer survival

A diagnosis of high cholesterol led to reduced mortality and improved survival in lung, breast, prostate and bowel cancer, a new researches reveals.

Colorectal cancer: cetuximab with FOLFOX improve patient outcomes

The combination of cetuximab with FOLFOX statistically significantly improved patient outcomes in RAS wild-type metastatic colorectal cancer patients.

Aspirin may prevent colon cancer relapse

Aspirin can be used to reduce mortality among colon cancer survivors as it may prevent cancer relapse, a new and unique study reports.

The important role of mental health in cancer recovery

Colorectal cancer patients with depression at time of diagnosis are more likely to have very poor quality of life after treatment, a new research shows.

EU approves treatment for advanced metastatic colorectal cancer

EU regulators approved the combined treatment of trifluridine/tipiracil for the treatment of adult patients with metastatic colorectal cancer.

RFA complemented immunotherapy in colorectal cancer patients

RFA was found to complement immunotherapy and induce systemic antitumor responses in colorectal cancer patients with liver metastasis.

Is colonoscopy necessary to colorectal cancer after resection?

Researchers report that post-operative colonoscopy is critically important for colorectal cancer patients to avoid cancer resection.

Ramucirumab: EU approval for lung and metastatic colorectal cancer

Ramucirumab received approval by the European Commission to be used as a treatment for advanced non-small cell lung cancer and metastatic colorectal cancer.

Panitumumab shows promise in metastatic colorectal cancer

Using panitumumab with best supportive care to treat metastatic colorectal cancer patients induced positive outcomes, according to a phase 3 study.

Cancer operation after chemo-radiotherapy: When should it be done?

A new analysis calculates the ideal waiting time between combined chemotherapy and radiation for rectal cancer and surgical removal of the cancer.

An additional treatment option for locally advanced rectal cancer

Treating patients with advanced rectal cancer with short-course radiation followed by consolidation chemotherapy before surgery led to positive outcomes.

New study sheds light to colorectal cancer recurrence

A new study comes to explain why metastatic colorectal cancer comes back after treatment with cetuximab to some patients.

FDA approves a toxic drug combination for colorectal cancer

The combination of trifluridine and tipiracil, once rejected because of its high toxicity levels, has being approved by the DFA for the treatment of colorectal cancer.

Drinking coffee daily may lower colon cancer recurrence

Coffee’s caffeine may help colon cancer patients keep the cancer away for longer, according to a new, large study.

Chemotherapy plus cetuximab benefited colorectal cancer patients

Patients with metastatic colorectal cancer who are mutation-free in specific genes benefited more from chemotherapy plus cetuximab than with chemotherapy alone.

New advances in the treatment of pre-treated metastatic colorectal cancer

Two treatments of metastatic colorectal cancer, regorafenib and TAS-102 proved to be beneficial for pre-treated patients, the results of new studies confirm.

New promising drug for metastatic colorectal cancer

A drug developed 50 years ago and abandoned because it was considered to be too toxic, has extended the life of colorectal cancer patients in a new clinical trial.

Gastrointestinal tumors associated with higher cancer risk

Patients with gastrointestinal stromal tumors may develop additional malignancies before and after their diagnosis, according to the first population-based study.

Metastatic colorectal cancer treatment approved in the USA

The US FDA has approved ramucirumab (trade name: Cyramza) for use in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer.

Daily aspirin may help prevent gastrointestinal cancers

Taking aspirin regularly and for a long time may decrease the risk of gastrointestinal cancer. However, the potential risks of prolonged aspirin use should be considered.

Minimally invasive surgery: a safe and effective option for rectal cancer

A new international study showed that minimally invasive surgery in rectal cancer patients is safe and associated with the same long-term cancer outcomes as open surgery.

Another reason to quit smoking after surviving colorectal cancer

Smoking after surviving colorectal cancer was found to double the risk of cancer-caused mortality compared to non-smoking survivors.

Metastatic colon cancer patients benefit from combination therapy

FOLFOXIRI combined with bevacizumab extended survival in patients with advanced colon cancer compared to the standard FOLFIRI chemotherapy with bevacizumab.

Ramucirumab extends survival for advanced colorectal cancer patients

Combining the targeted drug ramucirumab and FOLFIRI chemotherapy provides a survival advantage over standard treatment with FOLFIRI alone, a phase 3 study reports.

Surgery: unnecessary for patients with rectal cancer?

Similar survival rates measured on rectal cancer patients regardless of whether they had immediate surgery or pursued a “watch and wait” surveillance approach.

Vitamin D may help fight colon cancer

High levels of vitamin D linked to an average 33% increase on survival rate in patients with metastatic colorectal cancer.

Fecal screening for colorectal cancer increases polyp detection by 89%

The introduction of a program for colorectal cancer screening every 2 years in a region in France increased the rate of diagnosis of high-risk polyps by 89%.

Login to your account

Did you forget your password?